Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 3
2018 5
2019 6
2020 6
2021 13
2022 7
2023 7
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T, Katakura Y, Shimoda M, Kawasaki F, Yamabe M, Tatsumi F, Matsuki M, Iwamoto Y, Anno T, Fushimi Y, Kamei S, Kimura Y, Nakanishi S, Mune T, Kaku K, Kaneto H; COMING study Group. Kimura T, et al. Among authors: fushimi y. Diabetes Obes Metab. 2023 Dec;25(12):3632-3647. doi: 10.1111/dom.15258. Epub 2023 Aug 30. Diabetes Obes Metab. 2023. PMID: 37646192 Clinical Trial.
Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Katakura Y, Shimoda M, Ohnishi M, Kusano T, Dan K, Isobe H, Wamata R, Iwamoto Y, Fushimi Y, Sanada J, Obata A, Kimura T, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H. Katakura Y, et al. Among authors: fushimi y. Nutr Metab Cardiovasc Dis. 2023 Jul;33(7):1444-1452. doi: 10.1016/j.numecd.2023.02.011. Epub 2023 Feb 21. Nutr Metab Cardiovasc Dis. 2023. PMID: 37246074 Free article.
Correlation of Baba's diabetic neuropathy classification with various diabetes-related complications.
Iwamoto Y, Nakanishi S, Itoh T, Nakao E, Sugisaki T, Kusano T, Ohnishi M, Takenouchi H, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Hemmi S, Kimura T, Tatsumi F, Shimoda M, Mune T, Kaku K, Kaneto H. Iwamoto Y, et al. Among authors: fushimi y. Front Endocrinol (Lausanne). 2022 Oct 27;13:1054934. doi: 10.3389/fendo.2022.1054934. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36387868 Free PMC article.
Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: "The Earlier, the Better" in Therapy with Incretin-Based Medicine.
Kaneto H, Kimura T, Shimoda M, Obata A, Sanada J, Fushimi Y, Nakanishi S, Mune T, Kaku K. Kaneto H, et al. Among authors: fushimi y. Int J Mol Sci. 2021 Jul 24;22(15):7917. doi: 10.3390/ijms22157917. Int J Mol Sci. 2021. PMID: 34360682 Free PMC article. Review.
Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
Kimura T, Kubo M, Takahashi K, Wamata R, Iwamoto Y, Iwamoto H, Katakura Y, Sanada J, Fushimi Y, Shimoda M, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H. Kimura T, et al. Among authors: fushimi y. J Diabetes Res. 2024 Jan 4;2024:5880589. doi: 10.1155/2024/5880589. eCollection 2024. J Diabetes Res. 2024. PMID: 38223524 Free PMC article.
Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects.
Iwamoto Y, Kimura T, Dan K, Ohnishi M, Takenouchi H, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Shimoda M, Nakanishi S, Mune T, Kaku K, Kaneto H. Iwamoto Y, et al. Among authors: fushimi y. Front Endocrinol (Lausanne). 2023 Jul 31;14:1221723. doi: 10.3389/fendo.2023.1221723. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37583431 Free PMC article.
52 results